July 28, 2020 Bio/Pharma/CRO Lab Top-10 Licensing, IP, and Legal M&A, Partnerships

Thermo Fisher Scientific and Lyell Immunopharma Form Cell Therapy Manufacturing Partnership

Thermo Fisher Scientific and Lyell Immunopharma Form Cell Therapy Manufacturing Partnership Collaboration will include development of Thermo Fisher products and strategic manufacturing support WALTHAM, Mass., July 28, 2020 /PRNewswire/ — Thermo Fisher Scientific Inc., the world leader in serving science, and biotechnology company Lyell Immunopharma, are partnering to develop manufacturing processes designed to create more... Read more

July 22, 2020 Bio/Pharma/CRO Microscopy

Phase III data show Roche’s Port Delivery System with ranibizumab enabled over 98% of patients to go six months between treatments for neovascular age-related macular degeneration

In the Archway study, Port Delivery System with ranibizumab (PDS) demonstrated non-inferior and equivalent visual acuity outcomes compared with monthly ranibizumab eye injections, and a favourable benefit-risk profile PDS is a permanent refillable eye implant that continuously delivers a customised formulation of ranibizumab over a period of months, potentially reducing the treatment burden associated with... Read more

July 13, 2020 Bio/Pharma/CRO PAI Top-10 Product Launch

New data from phase IIIb study reinforces safety profile of Roche’s Hemlibra in people with haemophilia A

Basel, 13 July 2020 Second interim analysis of the STASEY study, including data from 193 patients, consistent with results from phase III HAVEN studies, with no new safety signals identified1,2,3 STASEY is the largest open-label study primarily assessing safety and tolerability of a medicine for haemophilia A with factor VIII inhibitors A separate analysis also... Read more

July 13, 2020 Bio/Pharma/CRO

Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer

Basel, 13 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced stage ovarian cancer.... Read more

July 8, 2020 Bio/Pharma/CRO Clinical Research/Diagn. Lab Top-10 M&A, Partnerships

Thermo Fisher Scientific Signs Companion Diagnostic Agreement with Chugai Pharmaceutical

Thermo Fisher Scientific Signs Companion Diagnostic Agreement with Chugai Pharmaceutical Agreement aims to expedite local biomarker testing of NSCLC patients eligible for entrectinib in Japan CARLSBAD, Calif., July 8, 2020 /PRNewswire/ — Thermo Fisher Scientific has signed a companion diagnostic (CDx) agreement with Chugai Pharmaceutical Co., Ltd., a member of the Roche Group, and has applied... Read more

June 25, 2020 Bio/Pharma/CRO Materials Analysis Product Launch

BURLINGAME, CA – June 25, 2020 – Halo Labs, a life science instrumentation company developing tools for biologics researchers, today announced it has launched its latest aggregate and particle identification system, called Aura™. Aura is the next generation of the Horizon®, Halo Labs’ popular Backgrounded Membrane Imaging (BMI) platform. With as little as 5 µL and a linear range... Read more

June 16, 2020 Bio/Pharma/CRO Lab Top-10 Product Launch

iSPA Workflow Helps Pharmaceutical Companies Bring New Drugs to Market Faster

Reliable, easy-to-use cryo-EM workflow solution quadruples throughput for pharma labs HILLSBORO, Ore., June 16, 2020 /PRNewswire/ — To help pharmaceutical companies obtain faster results in their drug discovery process and reduce the cost of bringing new drugs to market, Thermo Fisher Scientific has released the Thermo Scientific iSPA Workflow, the first commercially available single particle analysis (SPA) workflow... Read more

June 13, 2020 Bio/Pharma/CRO PAI Top-10

Positive phase III results for Venclexta/Venclyxto combination in acute myeloid leukaemia presented at EHA 2020

Basel, 13 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results from the phase III VIALE-A study, evaluating Venclexta®/Venclyxto® (venetoclax) in combination with azacitidine in people with previously untreated acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy. VIALE-A results were featured in the 25th European Hematology Association Virtual... Read more